Peer-reviewed veterinary case report
Airway sensitivity to adenosine in cats with chronic asthma
By Hirt, Reinhard A et al.·Published in Veterinary journal (London, England : 1997)·2011·Department for Small Animals and Horses·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Airway hyperresponsiveness to adenosine 5'-monophosphate in feline chronic inflammatory lower airway disease.
- Species:
- cat
Plain-English summary
A group of cats with chronic respiratory issues, including asthma and chronic bronchitis, underwent a test to see how their airways reacted to a substance called adenosine 5'-monophosphate (AMP). The test showed that cats with these conditions had a much stronger reaction compared to healthy cats, indicating inflammation in their airways. This suggests that the AMP challenge could be a useful tool for veterinarians to identify and monitor cats with lower airway diseases. The findings may help in tailoring treatments for affected cats, improving their breathing and overall health.
People also search for: cat asthma symptoms · chronic bronchitis in cats · how to treat cat respiratory issues
Abstract
Airway hyperresponsiveness is a key feature of human asthma and chronic bronchitis and response to the indirectly acting agonist adenosine 5'-monophosphate (AMP) is thought to reflect underlying airway inflammation. To examine whether airway responsiveness testing (ART) with AMP may be used to differentiate healthy cats from those with asthma (FA) and chronic bronchitis (CB), 24 cats (9 FA, 6 CB, 9 controls) underwent ART with AMP at concentrations of 0.1, 1, 10, 100 and 500mg/mL using barometric whole body plethysmography. The defined endpoint of ART, an increase in enhanced pause (Penh) exceeding 300% of the post-saline value (baseline), was reached in 9/15 patients (7 FA, 2 CB), but in none of the controls. Mean Penh (±SD) at baseline (BL) was 0.49±0.16 for cases, and 0.54±0.16 for controls, and was significantly increased after AMP challenge in clinical cases (2.62±2.20), but not in controls (0.63±0.30, P<0.05). After separating responder (R) and non-responder (NR) cases, a more pronounced difference after challenge was found (R: 3.96±1.84, NR: 0.6±0.21, P<0.001). The provocative concentration of the agonist that increased Penh to 300% of BL (PC Penh 300) in R cases was 52.98±48.04mg/mL AMP. Age had no influence on the responder status or PC Penh 300. It was concluded that AMP challenge may offer a new method for the identification of cats with lower inflammatory airway disease, and possibly for monitoring disease progression or response to therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19910226/